These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21829720)

  • 21. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development?
    van Gils MJ; Schuitemaker H
    Curr HIV Res; 2010 Dec; 8(8):579-86. PubMed ID: 21054254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.
    Dong M; Zhang PF; Grieder F; Lee J; Krishnamurthy G; VanCott T; Broder C; Polonis VR; Yu XF; Shao Y; Faix D; Valente P; Quinnan GV
    J Virol; 2003 Mar; 77(5):3119-30. PubMed ID: 12584337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines.
    Liu L; Wan Y; Xu J; Huang X; Wu L; Liu Y; Shao Y
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1396-404. PubMed ID: 18184083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses.
    Huang X; Zhu Q; Huang X; Yang L; Song Y; Zhu P; Zhou P
    Vaccine; 2017 Apr; 35(16):2042-2051. PubMed ID: 28318765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.
    Buonaguro L; Racioppi L; Tornesello ML; Arra C; Visciano ML; Biryahwaho B; Sempala SD; Giraldo G; Buonaguro FM
    Antiviral Res; 2002 Jun; 54(3):189-201. PubMed ID: 12062391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.
    Mouquet H; Klein F; Scheid JF; Warncke M; Pietzsch J; Oliveira TY; Velinzon K; Seaman MS; Nussenzweig MC
    PLoS One; 2011; 6(9):e24078. PubMed ID: 21931643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
    van Gils MJ; Edo-Matas D; Schweighardt B; Wrin T; Schuitemaker H
    J Gen Virol; 2010 Jan; 91(Pt 1):250-8. PubMed ID: 19793903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade.
    Zhang C; Wan Y; Shi J; Zhou M; Meng Z; Yuan S; Qiu C; Zhang X; Xu X; Liu C; Xu J
    AIDS Res Hum Retroviruses; 2010 May; 26(5):569-75. PubMed ID: 20455767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
    Muthumani K; Zhang D; Dayes NS; Hwang DS; Calarota SA; Choo AY; Boyer JD; Weiner DB
    Virology; 2003 Sep; 314(1):134-46. PubMed ID: 14517067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses.
    Jacob RA; Abrahams F; Tongo M; Schomaker M; Roux P; Mpoudi Ngole E; Burgers WA; Dorfman JR
    J Virol; 2012 Jul; 86(14):7699-703. PubMed ID: 22573859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection.
    Dreja H; O'Sullivan E; Pade C; Greene KM; Gao H; Aubin K; Hand J; Isaksen A; D'Souza C; Leber W; Montefiori D; Seaman MS; Anderson J; Orkin C; McKnight A
    J Gen Virol; 2010 Nov; 91(Pt 11):2794-803. PubMed ID: 20685933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK; Vlachogiannis G; Bosch KA; Stamatatos L
    J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.